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Summary In this study we measured S-1i OB using a recently developed luminometric immunoassay with a detection limit of 0.02 gg l-1. By
measuring serum S-1O0B concentrations in 58 apparently healthy individuals a reference value of 0.16,ug 1-1 was found. To assess the
sensitivity of the assay we measured levels of S-100B protein in the serum of 251 patients with cutaneous malignant melanoma before the
start of treatment. Only one of 179 patients with limited disease had a serum concentration higherthan the reference value, whereas elevated
levels were seen in 79% of patients with metastasized disease. In the latter group the NSE serum concentration was elevated in 42%. Using
a receiver operating characteristic (ROC) curve it is shown that S-100B is a significantly better parameter than neuron-specific enolase (NSE)
for distinguishing patients with limited disease from those with extensive melanoma. Pretreatment S-100B values were highly predictive for
the period of survival. Patients with limited disease have increased risk for early death with increasing levels of S-100B protein. Within the
group of patients with positive lymph nodes and/or with distant metastases, elevated S-100B levels strongly identified high-risk patients. Our
study indicates that the measurement of S-1QOB as a tumour marker in the management of patients with cutaneous malignant melanoma has
clinical significance.
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The use oftumour markers in melanoma was initially limited to the
measurement of neuron-specific enolase (NSE), which is the y
isoenzyme of the enolase enzyme (Wibe et al, 1990). Results have
been disappointing and this assay has notgained aplace inthe moni-
toring of patients treated for malignant melanoma. The demonstra-
tion that the S-100 protein is expressed in cultured melanoma cells
(Gaynor et al, 1980) opened the way for investigations into the pres-
ence ofthe S-100 protein in a variety oftissues. As the protein was
initially extracted from brain tissue it was not surprising that the
molecule was detected in other tissue apart from melanocytic cells
(Cochran et al, 1993). The S-100 protein family belongs to the EF-
hand proteins, and to date 17 different proteins have been assigned
to this family (Schafer and Heizmann, 1996). S-1OOB is formed by
homodimers consisting oftwoP subunits orheterodimers of x and f
subunits with equal molecular mass of 10.5 Da. The isoform a,B is
found in melanocytes and the DP is found in high concentrations in
glial cells and Schwann cells. S-IOOAI (aaox) is found in striated
muscle, heart and kidney (Baudier et al, 1986).
The function of S-100 is not known exactly but its biochemical
properties strongly suggest that it activates cell processes along the
Ca2+ signal-transduction pathway (Schafer and Heizmann, 1996).
By using monoclonal antibodies against the different isoforms a
specific test was developed. Measurement ofthe S-1OOB protein in
serum has been possible for several years but the assessment ofthe
usefulness of this protein as a tumour marker for malignant
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melanoma was hampered by the low sensitivity of the available
assay (Fagnart et al, 1988).
The availability ofarecently developed, more sensitive test, has
prompted us to measure the concentration of S-1OOB in pretreat-
ment sera from patients with malignant melanoma and assess its
relationship with stage. The results were compared with measure-
ments ofNSE in the same samples. The possible predictive power
of the pretreatment S-1OOB level as an additional independent
parameter for survival was investigated.
MATERIALS AND METHODS
Patients
Serum taken before in-house treatment was available from 251
patients, 143 female subjects and 108 male subjects, who were
seen at the Netherlands Cancer Institute in the period 1984-94.
Their age ranged from 12 to 87 years with a mean age of 50.6
years. The median follow-up time was 67 months with a range of
1-147 months.
The disease stage was determined according to the M.D.
Anderson Cancer Centre classification for cutaneous melanoma
(Smith, 1976).
Histological classification showed that 46 patients (18%) had
superficial spreading, 33 (12%) had nodular melanoma.
Amelanotic melanoma was found in 15 (6%) of the cases. Acral
lentiginous melanoma was found in 14 (6%). Malignant blue naevi
were detected in two and lentigo maligna melanoma in four cases.
The pathological diagnosis was not otherwise specified in 138
(55%) patients. Serum from 16 individuals who were treated for
various benign skin disorders was also included.
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Table 1 Pretreatment serum concentration of S-10OB and neuron-specific enolase
n Median Min/max Above 95 percentilea
S-100B
Stage 155 0.04 ND-0.16 0
Stage II 15 0.05 ND-0.16 0
Stage IIIA 8 0.07 0.04-0.19 1 (12%)
Stage IIIB 54 0.07 ND-4.69 18 (33%)
Stage IV 19 1.12 ND-123.0 15 (79%)
NSE
Stage 155 5.4 1.8-13.0 1 (1%)
Stage II 15 5.6 4.0-8.6 0
Stage IIIA 8 5.2 3.8-9.4 0
Stage IIIB 53 5.4 2.1-49.6 3 (6%)
Stage IV 19 8.0 4.7-92.3 8 (42%)
Median values and range of pretreatment serum concentration of S-100B and NSE in patients with malignant melanoma.
Results are expressed in gg I-1. aThe 95 percentile used for S-1O0B was 0.16 9g1-' as found in this study. For NSE 12.5,g l-'
was used as cut-off level (Body et al, 1992).
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Figure 1 Distribution of pretreatment serum S-10OB levels in healthy
individuals (n = 58), patients with benign skin disease (n = 16) and cutaneous
malignant melanoma, stage (n = 155), stage 11 (n = 15), stage IIIA (n = 8),
stage IIIB (n = 54) and stage IV (n = 19). Horizontal lines represent the
median values
To establish a reference range forthis new assay we measured the
S-1OOB concentration in 58 normal individuals (41 men and 17
women), who voluntarily donated blood for this occasion. The
average age ofthis group was 62 years, ranging from 40 to 90 years.
Marker assays
The Sangtec S-100 luminescence immunoassay (LIA) is a two-site
immunoluminometric test based on three monoclonal antibodies
that specifically bind to the I subunit of the S-1OOB protein. The
assay detects the 11 and 4: dimer in serum (Nyberg et al, 1996).
The standard range is 0.1-20 jig 1-' and a lower detection limit
of 0.02 jig 1-1 was established. Day to day variation was found to
be 5% at the level of 1.0 jig 1-' as well as at 10 jg 1-'.
The LIA-mat® NSE Prolifigen® assay determines specifically
the y subunit ofthe enolase enzyme. The reference value has been
established at 12.5 jg 1-1 (Body et al, 1992). The standard range is
from 2 to 200 jig 1-1 and typical day to day CVs were 9% at the
lower end and 6% at higher standard levels.
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Figure 2 Receiver operating characteristic (ROC) curves for S-100B (-)
and NSE --- -) in predicting the presence of extensive disease (stage IIIB
and IV) in cutaneous malignant melanoma. The area under the curve was
significantly different for S-1O0B and NSE
Statistical methods
The Kruskal-Wallis test is used to compare more than two groups.
For the multivariate survival analysis we used the Cox regression
model (Cox, 1972). The Spearman coefficient of correlation was
used for calculation ofcorrelation between two variables.
Areas under the curve (AUC) for receiver operating character-
istic (ROC) curves were compared using the method of Hanley
and McNeil (1983).
Constructions of survival curves were carried out according to
Kaplan-Meier. Comparisons were performed with the log-rank test.
RESULTS
The 95 percentile of the group of normal individuals was estab-
lished at 0.16 ,ug 1-'. In 24 of the 58 serum samples we could not
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Figure 3 Survival curves of 251 patients with malignant melanoma
according to stage. A total of 155 patients had stage (-), 23 stage 11 and
IIIA (...), 54 stage IIIB (--- -) and 19 stage IV (c c v). Difference between
survival in relation to stage is significant (P < 0.0001)
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Figure 4 Survival curves of 251 patients with malignant melanoma
according to the pretreatment serum S-100B level. A positive level
(> 0.16gg 1-') was found in 36 patients (--- -). Levels within reference range
were found in 215 ( ). Difference of survival is highly significant (P< 0.0001)
detect any S-100 protein. The highest value found in this group
was 0.27 jg 1-'.
In the 16 patients with benign skin disorder the median S-100
protein concentration could not be calculated because 11 (69%) of
the samples had a concentration below the detection limit of
0.02 jig 1-1. The highest level found was 0.06 jg 1-1.
The results of the group of patients with malignant melanoma
are shown in Table 1. Of the 155 patients with stage I malignant
melanoma, 45 (29%) did not have measurable amounts of S-100
protein in pretreatment serum. Fifteen patients (6.0%) had stage II
melanoma. In three (20%) patients S-1OOB was undetectable.
Eight patients (3.2%) had stage IIIA disease. In all of these
patients S-bOOB could be detected. Interestingly, 11 of54 (21.5%)
patients with stage IIIB and 1 of 19 with stage IV had undetectable
levels of serum S-1OOB at presentation. A scatterplot of the
S-1OOB concentrations is given in Figure 1.
A Kruskal-Wallis analysis of variance showed a highly signifi-
cant difference in serum concentration of S-lOOB protein between
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Figure 5 Survival curves of 178 patients with malignant melanoma, limited
disease stage or Ila. A total of 41 patients had S-1O0B levels > 0.06 gg I-'
(--- -), 61 with S-100B between 0.03 and 0.06 (...) and the remaining group of
76 had levels < 0.03 gg 1- (-). The group with levels > 0.06 gg 1-' had a
worse prognosis (P= 0.01)
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Figure 6 Survival curves of 55 patients with positive lymph nodes, stage
IIIB. Nineteen had elevated pretreatment S-100B levels (> 0.16 ig 1-') (- -)
and 36 levels within our reference range (-). Difference between survival
time is significant (P < 0.0001)
stages (P < 0.00001). NSE levels showed a less significant differ-
ence (P = 0.0001).
If levels over 0.16 jg 1-1 are considered to be elevated, all
patients, with the exception ofone with stage IIIA (this patient had
a level of 0.19 ,ug 1-1 and developed lung metastases 11 months
later and died 1 year afterwards), with abnormal S-1OOB protein
concentrations had stage IIIB or IV disease. NSE levels over
12.5 jg were also found mainly in the higher stages, but the sensi-
tivity was considerably lower. A ROC curve of S-1OOB and NSE
distinguishing between stages I, II and stage IIIA vs IIIB and IV is
shown in Figure 2. The AUC for S-1OOB was 0.73 ± 0.040
compared with 0.59 ± 0.045 for NSE. This difference is highly
significant. At 99% specificity the sensitivity of S-1OOB is 47%
compared with 30% for NSE. Because S-1OOB was shown to be
superior to NSE with respect to sensitivity and specificity we have
not included NSE in the survival analyses.
Survival of malignant melanoma patients is related to stage. In
the group of patients with limited disease (stage I and II) 5-year
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Table 2 P-values stepwise Cox regression analysis
Variable 0 1 2 3 4 5
Stage 0.0000 0.0000 0.0000 0.0000 0.0000 0.1397
Age 0.0362 0.0548 0.0535 0.4717 0.1831 0.1767
PA-diag 0.0073 0.0020 0.0034 0.0020 0.0247 0.0153
Sexe 0.0824 0.6474 0.4893 0.3248 0.3368 0.5252
Stage *PA-diag 0.0000 0.0053 0.3216 0.2878 0.0453 0.0275
NSE 0.0643 0.3216 0.1505 0.9717 0.8862 0.4919
S-100B 0.0000 0.0000 0.0000 0.0000 0.0000 0.7175
Stage *S-100B 0.0000 0.0000 0.0000 0.1495 0.0184 0.0190
PA-diag*S-100B 0.0058 0.1310 0.0446 0.0131 0.0207 0.0047
This table shows the results of the Cox regression. In the first block the traditional variables and their interactions were entered. Because of non-linearity of
S-1OOB, S-1O0B and NSE were divided into five groups: S-1O0B (pgI-'), .0.02 (60); 0.03-0.04 (60); 0.05-0.06 (46); 0.07-1.0 (38); >1.0 (47); and NSE (pg 1-'),
1.8-4.3 (49); 4.4-5.0 (47); 5.1-5.8 (58); 5.9-6.7 (45); >6.8 (51). After correction for stage (P< 0.0001) and PA-diagnosis (P= 0.0020), S-1O0B was still highly
significant (P < 0.0001). After entering these three variables there were interactions* between PA-diagnosis and S-1QOB (P = 0.0131) and between stage and
S-1O0B (P = 0.0184), which were also entered in the model. Underlined values are entered in the model.
survival was 79% compared with 28% for patients with dissemi-
nated disease (Figure 3).
The predictive value of an elevated S-1OOB level (i.e.
> 0.16 ,ug 1-') for survival of patients with malignant melanoma
is demonstrated by the Kaplan-Meier curve shown in Figure 4.
The median survival of the group with elevated pretreatment
S-1OOB (n = 36) levels was 7 months, whereas the group of
patients with normal S-1OOB concentration (n = 215) had a median
survival of more than 12 years (P < 0.0001).
Data on initial tumour thickness were available from 148
patients with stage I, II and IIIA. In a Cox regression model the
Breslow thickness ofthe tumour (Breslow, 1970) was more signifi-
cantly correlated with survival than S-1OOB level. After correcting
for thickness, S-1OOB was still a significant factor (P = 0.02).
To illustrate the relation of the pretreatment serum S-1OOB
concentration and survival we created three subgroups of com-
parable size. The first group (n = 41) with a level > 0.06 tg 1-1,
a second (n = 76) with concentrations < 0.03 ug 1-' and the
remaining patients had a S-1OOB serum concentration between
0.03 and 0.06 jg 1-' (Figure 5). The subgroup with the higher
S-IOOB values had a significantly shorter survival (P = 0.01).
Patients with stage IIIB and apretreatment serum concentration of
S-IOOB below 0.16gg 1- (n = 36) survived significantly longer than
the group with high stage and increased pretreatment S-1OOB levels
(n = 19, Figure 6). The median survival of the latter group was 7
months compared with 34 months for the formergroup (P < 0.0001).
Stage IV with elevated S-1OOB levels also had a significantly
shorter survival than those with levels within the reference range,
although all patients died within 2 years.
A stepwise Cox regression analysis was performed to see
whether S-1OOB and NSE provided additional contributions to
prognosis using stage, age and tumour histology as variables.
After correction for stage (P < 0.0001) and histology (P = 0.003),
S-1OOB was still a strongly significant factor (P < 0.0001).
Possible interactions between the parameters were entered in this
statistical model (Table 2).
DISCUSSION
The S-100 protein has been the most practical marker for
melanocytic tumours in immunohistochemistry. They may increase
the accuracy of melanoma staging and detect metastatic tumour
cells not detectable by conventional histology (Cochran et al, 1982).
A promising marker may be a metabolic product of melatonin
such as 5-s-cysteinyldopa, and more recently it was reported that
the level ofsoluble intercellular molecule 1 (ICAM-1) is increased
in serum of patients with advanced melanoma (Hirai et al, 1997).
Both markers seem to have disadvantages, however. Positive 5-s-
cd levels were only found in patients with metastatic disease, and
sICAM-I serum levels did not decrease in patients who underwent
surgery, which suggests that the serum concentration is not related
to tumour stage. NSE is not useful because of the relatively low
sensitivity of 25% for extensive disease (Bei Guo et al, 1995).
In this study we measured serum concentrations of S-1OOB in
patients with cutaneous malignant melanoma using the newly
developed immunoluminometric assay LIA S-100 (Nyberg et al,
1996). By using an improved labelling system quantification of
S-100 protein became possible at the level of0.02 jg 1-1.
Von Schoultz et al (1996) did not find levels over 0.20 ,ug 1- in
81 healthy persons, which is in line with our finding that 95% of
our healthy group had levels below 0.16 gg 1-'. This is not a defin-
itive cut-offlimit because ofthe relatively small number ofcontrol
subjects, but it is in line with the finding by others, using the less
sensitive immunoradiometric assay, that the geometric mean of
healthy individuals is below 0.1jIg 1-' (Bei Guo et al, 1995; Von
Schoultz et al, 1996).
Earlier studies concerning the S-100 serum concentration in
patients with malignant melanoma reported lower incidences of
elevated S-100 serum levels (Fagnart et al, 1988; Missler and
Wiesmann, 1995). The assays in these studies were not based on
the same technique, did not use the same antibodies and detection
limits of0.15 jig 1-' or higher were found.
Previous studies with the more insensitive immunoradiometric
assay (IRMA) using pretreatment serum samples of patients with
cutaneous malignant melanoma reported a relation between stage
of the disease and the median concentration of S-1OOB protein,
although an adequate assessment of the sensitivity of the S-1OOB
was not possible (Von Schoultz et al, 1996; Henze et al, 1997). Bei
Guo et al (1995) found positive S-1OOB values in 13% of stage
IIIB patients, contrary to 33% in this study.
In this study we confirmed a significant correlation between stage
and disease. Levels of S-G00 over 0.16 ,ug 1-' indicate extensive
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disease, and stage I and IIA patients were inclined to have serum
levels below 0.16 ,tg 1-1.
The finding that 85% of patients with metastatic disease had
elevated S-1OOB concentrations is notable. This result suggests
that S-100 has at least an equal sensitivity for malignant melanoma
as established tumour markers in other situations, e.g. CA 125 in
ovarian carcinoma (Tuxen et al, 1995).
The prognosis for patients with malignant melanoma is deter-
mined by the stage of the disease. The M.D. Anderson classifica-
tion for staging does not include the tumour thickness or level of
invasion, two features known to affect prognosis. Especially in
cases of limited disease, stage I and II, tumour thickness is consid-
ered to be the single most important prognostic factor (Balch et al,
1992). The finding that S-1OOB was a significant independent
prognostic factor after correction for tumour thickness has not
been reported before. The fact that the expression of the D subunit
ofS-l00 protein in malignant melanoma is associated with vertical
growth and invasiveness may be responsible for this unique result
(Cho et al, 1990).
Pretreatment serum levels of S-1OOB protein can identify
patients with a high risk ofearly death in the group ofpatients with
stage IIIB and stage IV disease. This may have implications in the
treatment to be chosen.
The classification used for staging does not allow us to differen-
tiate this group ofpatients according to the number oflymph nodes
that were found positive during surgical exploratory procedures.
However, ongoing trials to study the effect of the search for
sentinel nodes (Day and Lew, 1985) may facilitate the validation
of S-IOOB protein as a marker for extensive disease.
The most important application of tumour markers has been as
an indicator for recurrence during follow-up. It has been shown
that serial determinations of the serum S-1OOB concentration may
be of help in the assessment of response to treatment (Bei Guo et
al, 1995; Missler and Wiesmann, 1995). In a recent study it was
found that in patients with high risk of recurrence and an elevated
level of S-1OOB at any moment after initial treatment had a signi-
ficantly shorter time to relapse than the group with no elevation
(Miliotes et al, 1996). The relatively low incidence (48%) of
elevated levels in this publication might be due to the insensitivity
of the assay used. It is important to investigate the use of the LIA
S-100 assay to detect recurrence at an early stage and so enhance
the effectiveness ofrepeated treatment.
The availability of this sensitive assay for the detection of S-
1OOB protein in serum will improve the utility of the protein as a
marker for early recurrence as successive increases of the marker
at low concentrations may indicate relapse.
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